BioSpace News Archive

A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.

Milestone Scientific Inc. provided a business update and announced financial results for the first quarter ended March 31, 2022.

Talaris Therapeutics, Inc. announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company’s Board of Directors.

Sol-Gel Technologies, Ltd. announced that that the Company will present at the upcoming H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today provided an update on recent progress achieved in its ongoing pivotal Phase 3 InnovAATe clinical trial evaluating the safety and efficacy of the Company’s proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Calithera Biosciences, Inc. announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announces the first sample shipment of its recombinant spider silk fibers and fabrics for use and evaluation into a range of biomedical applications.

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, announced data emerging from the Company’s recently unveiled iPSC-based gamma-delta T cell platform.

ProMIS Neurosciences, Inc. announced its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17th.

Codiak BioSciences, Inc. announced new preclinical data on the Company’s engEx-AAV™ discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus vector gene therapy.